GLucose Monitoring Programme SingaporE, Phase 2 (GLiMPSE2)
NCT04564911 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 206
Last updated 2023-12-21
Summary
Many with type 2 diabetes (T2D) remain sub-optimally controlled. Structured programmes requiring dietary and lifestyle intervention have been shown to improve control but are time-and labour-intensive. The role for self-monitoring of blood glucose with capillary blood glucose (CBG) readings is uncertain. The use of flash glucose monitoring (FGM) with education may effect improvements in awareness and self-management behaviour and hence glycaemic control.
The investigators aim to compare the effects of FGM versus CBG fingersticks in the context of a structured education programme over a 6-month period in adults with type 2 diabetes. 200 adults (\>21y) with sub-optimally controlled T2D (7.5-10%) on either diet-controlled, oral glucose lowering drugs or background insulin will be enrolled and randomised into the intervention arm (FGM and education) or control arm (capillary glucose fingersticks and education). The intervention arm will monitor glucose using FGM continuously for 6 weeks and intermittently thereafter up to 24 weeks. The control group will monitor glucose using CBG fingersticks up to 24 weeks. During the intervention period(0-24w), both arms will undergo the same schedule of visits (-2w, 0w, 8w, 16w, 24w) and 6 education sessions. Both groups will be followed up at weeks 38 and 52. Primary outcome is HbA1c change from baseline at 24 weeks. This study will provide novel data on the use of FGM versus CBG in Type 2 diabetes and its impact on glycaemic control.
Conditions
- Diabetes Mellitus, Type 2
- Flash Glucose Monitoring
Interventions
- COMBINATION_PRODUCT
-
Flash Glucose Monitoring and Education
Participants will wear the flash glucose monitoring system, and receive an education package on how to self-manage their glucose levels. They will use the flash glucose monitoring system continuously for 6 weeks. From week 6 to week 24, the frequency of use of flash glucose monitoring will be reduced to one sensor every 4 weeks. They will receive education at weeks 0, 2, 8 and 16. They will also wear a blinded sensor for the last 2 weeks of the intervention period (week 25 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
- COMBINATION_PRODUCT
-
Capillary glucose monitoring and Education
Participants will use a capillary glucose meter and receive an education package on how to self-manage their glucose levels. Participants will be encouraged to test their blood glucose levels at least twice a day, but preferably 4 times daily: pre-meal and bedtime blood glucose levels. They will receive education at weeks 0, 2, 8 and 16. They will wear a blinded sensor again after the last 2 weeks of the intervention period (week 24 to week 26). After the first 24 weeks, participants enter the observation phase (weeks 38 to 52) wherein they will be encouraged to continue monitoring their glucose levels through capillary glucose monitoring, during pre-meals and bedtime daily.
Sponsors & Collaborators
-
National University Hospital, Singapore
collaborator OTHER -
SingHealth Polyclinics
collaborator OTHER -
National Healthcare Group Polyclinics
collaborator OTHER_GOV -
National University Polyclinics, Singapore
collaborator OTHER -
Singapore General Hospital
lead OTHER
Principal Investigators
-
Daphne SL Gardner, MD · Singapore General Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 21 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-12-22
- Primary Completion
- 2023-09-30
- Completion
- 2023-12-30
Countries
- Singapore
Study Locations
More Related Trials
-
A Study of LY3185643 and rGlucagon in Healthy Participants
NCT02951780 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
NCT02964572 ·Status: COMPLETED ·Phase: NA
-
Development and Implementation of Ramadan Fasting Algorithm for Singaporeans With Type 2 Diabetes
NCT03314246 ·Status: COMPLETED ·Phase: NA
-
Foxiga Korea Local Phase 4 Study
NCT02564926 ·Status: COMPLETED ·Phase: PHASE4
-
24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
NCT00318656 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease
NCT01018173 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes
NCT04219124 ·Status: COMPLETED ·Phase: PHASE4
-
SGLT2i, Pioglitazone, and Ketone Production in T2D
NCT07053319 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Performance of the Glyconics-SX System (ANODE02)
NCT05476016 ·Status: COMPLETED ·Phase: NA
-
Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
NCT01947855 ·Status: COMPLETED ·Phase: PHASE3
-
Glucokinase Activator in Monogenic Diabetes
NCT06976658 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
NCT00744926 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Empagliflozin in GSD-Ib Patients
NCT05960617 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions
NCT05721729 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of NGM282 in Patients With Type 2 Diabetes
NCT01943045 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
NCT06571591 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
NCT00744367 ·Status: COMPLETED ·Phase: PHASE3
-
Multicenter, Prospective, Observational Study on the Treatment of Type 2 Diabetes With Proline Plus Empagliflozin Tablets
NCT07023172 ·Status: RECRUITING
-
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
NCT00909597 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
NCT01439854 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
NCT03499704 ·Status: COMPLETED ·Phase: PHASE4
-
To Evaluate the Response to Glucagon During Hypoglycemia
NCT00817271 ·Status: COMPLETED ·Phase: PHASE1
-
SGLT2i, Hepatic Glucose Production, and SNS
NCT07053293 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin
NCT02426294 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
NCT05029115 ·Status: ENROLLING_BY_INVITATION